Reports Q1 revenue $169.172M, consensus $163.75M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “We had a strong start to the year with $169 million of revenue, which represented 14% organic non-COVID growth and helped drive meaningful adjusted operating margin expansion. Total orders grew nearly 20%, with all four franchises growing double-digits, highlighting the momentum in our business. As a result, we are confident in our organic growth outlook for the full year. Strategically, we strengthened our Analytics franchise with the acquisition of 908’s bioprocessing portfolio. Finally, we are working to navigate through the current economic environment and at this point in time, we see minimal impact from tariffs on our EPS.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Is RGEN a Buy, Before Earnings?
- Repligen price target lowered to $150 from $170 at Canaccord
- Repligen price target lowered to $202 from $219 at RBC Capital
- Repligen appoints Jacob Johnson as VP, investor relations
- Promising Outlook for Repligen: Strong Order Momentum, Strategic Positioning, and Growth Opportunities